ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

  • Abstract Number: 2543 • 2012 ACR/ARHP Annual Meeting

    Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents

    Jeffrey R. Curtis1, Shuo Yang2, Nivedita M. Patkar3, Lang Chen4, Jasvinder A. Singh5, Grant W. Cannon6, Ted R. Mikuls7, Elizabeth S. Delzell8, Kenneth G. Saag9, Monika M. Safford10, Scott DuVall11, Kimberly Alexander12, Pavel Napalkov12, Aaron Kamauu13 and John Baddley14, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, 4Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Department of Medicine, University of Alabama, Tuscaloosa, AL, 6Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, 7Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 8Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 9Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, 10Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, 11VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 12Epidemiology, Genentech, Inc., South San Francisco, CA, 13Anolinx, Bountiful, UT, 14Medicine, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Risks of hospitalized infections for newer biologic agents have not been well characterized compared to risks for anti-TNF therapy. Purpose: To compare the risk…
  • Abstract Number: 2168 • 2012 ACR/ARHP Annual Meeting

    Tolerance and Efficacy of Rituximab in Elderly Patients with Rheumatoid Arthritis Enrolled in the French Society of Rheumatology Air Registry

    Sarah Payet1, Jacques-Eric Gottenberg2, Xavier Mariette3, Philippe Ravaud4, Elodie Perrodeau5, Thomas Bardin6, Patrice Cacoub7, Alain G. Cantagrel8, Bernard Combe9, Maxime Dougados10, Rene-Marc Flipo11, Bertrand Godeau12, Loic Guillevin13, Xavier X. Le Loet14, Eric Hachulla15, Thierry Schaeverbeke16, Jean Sibilia17, Isabelle Pane18, Gabriel Baron19 and Martin Soubrier20, 1Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, 2Rheumatology, Strasbourg University Hospital, Strasbourg, France, 3Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, 4Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 5Epidemiologist, Paris, France, 6Rheumatology, Hôpital Lariboisière, Paris, France, 7Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 8Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, 9Rheumatology, Hopital Lapeyronie, Montpellier, France, 10Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 11Rheumatology, Hopital R Salengro CHRU, Lille, France, 12Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 13Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 14Rheumatology Department, CHU de ROUEN, Rouen, France, 15Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 16Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 17Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 18Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, 19Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, 20Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France

    Background/Purpose: This study aimed to compare the efficacy and the safety of Rituximab (RTX)in elderly (aged ≥ 65years) and younger patients (aged 18-64 years) with…
  • Abstract Number: 1758 • 2012 ACR/ARHP Annual Meeting

    Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy

    Elena Becerra1, Inmaculada de la Torre2, Maria J. Leandro3 and Geraldine Cambridge3, 1Rheumatology, University College London, London, United Kingdom, 2Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, 3Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: B-cell-activating-factor (BAFF) coordinates differentiation of B cells into immunoglobulin secreting cells (ISC) by binding to 3 different receptors (BBRs), namely BAFF-R, transmembrane activator and…
  • Abstract Number: 1753 • 2012 ACR/ARHP Annual Meeting

    A Rheumatoid Factor Paradox: Inhibition of Rituximab-Induced Complement Dependent Cytotoxicity of B Cells

    Jonathan D. Jones1, Irene Shyu2, Marianna M. Newkirk3 and William F. C. Rigby2, 1Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 3Medicine, McGill University Health Centr, Montreal, QC, Canada

    Background/Purpose:   Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of IgG antibodies.  It is found in ~80% of patients with rheumatoid…
  • Abstract Number: 1757 • 2012 ACR/ARHP Annual Meeting

    B Cell Activating Factor Receptor Expression After Rituximab: Comparison of Patients with Rheumatoid Arthritis and Thrombotic Thrombocytopenic Purpura

    Elena Becerra1, Maria J. Leandro1, Edward O. Heelas2, John P. Westwood2, Inmaculada de la Torre3, Marie A. Scully2 and Geraldine Cambridge1, 1Rheumatology, Rheumatology, University College London, London, United Kingdom, 2Hematology, Hematology, University College London, London, United Kingdom, 3Rheumatology, Rheumatology, Gregorio Marañón Hospital, Madrid, Spain

    Background/Purpose: B cell depletion therapy based on rituximab (RTX) is an effective therapy for Rheumatoid Arthritis (RA) and for Thrombotic Thrombocytopenic Purpura (TTP). Serum B…
  • Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting

    Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry

    Jean Hugues Salmon1, Patrice Cacoub2, Bernard G. Combe3, Jean Sibilia4, Beatrice Pallot Prades5, Olivier Fain6, Alain G. Cantagrel7, Maxime Dougados8, Olivier Meyer9, Philippe Carli10, Edouard Pertuiset11, Isabelle Pane12, Philippe Ravaud13, Xavier Mariette14 and Jacques-Eric Gottenberg15, 1Rheumatology, Reims, France, 2Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 3Rhumatologie, Hopital Lapeyronie, Montpellier, France, 4Rheumatology, CHU Hautepierre, Strasbourg, France, 5Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, 6Internal Medicine, Jean Verdier Hospital, Bondy, France, 7Rheumatology, Place du Docteur Baylac, Toulouse, France, 8Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 9Rheumatology, Hopital Bichat, Paris, France, 10HIA sainte Anne, Toulon, France, 11Rheumatology, Ch Rene Dubos, Pontoise, France, 12Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, 13Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 14Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, 15Rheumatology, Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…
  • Abstract Number: 1305 • 2012 ACR/ARHP Annual Meeting

    Three-Year Follow-up of Rituximab in Rheumatoid Arthritis: Results From the Belgian MIRA (MabThera in Rheumatoid Arthritis) Registry

    Filip De Keyser1, Patrick Durez2, Rene Westhovens3, marie-Joelle Kaiser4 and Ilse Hoffman5, 1Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 2Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, 3Rheumatology, University Hospital KU Leuven, Leuven, Belgium, 4Rheumatology, Dept Rheumatology, University Hospital Liege, Belgium, Belgium, 5Rheumatology, Dept Rheumatology, GZA St-Augustinus Hospital Antwerp, Belgium, Wilrijk, Belgium

    Background/Purpose: The MIRA registry was set up to collect safety, efficacy and (re)treatment practice data for Belgian RA patients treated with rituximab. Methods:  All rheumatologists…
  • Abstract Number: 1308 • 2012 ACR/ARHP Annual Meeting

    Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry

    Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Patrice Cacoub4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Bertrand Godeau9, Loic Guillevin10, Xavier X. Le Loet11, Eric Hachulla12, Thierry Schaeverbeke13, Jean Sibilia14, Isabelle Pane15, Gabriel Baron16 and Xavier Mariette17, 1Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 3Rheumatology, Hôpital Lariboisière, Paris, France, 4Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 5Rheumatology, Place du Docteur Baylac, Toulouse, France, 6Rheumatology, Hopital Lapeyronie, Montpellier, France, 7Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 8Rheumatology, Hopital R Salengro CHRU, Lille, France, 9Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 10Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 11Rheumatology Department, CHU de ROUEN, Rouen, France, 12Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 13Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 14Rheumatology, CHU Hautepierre, Strasbourg, France, 15Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, 16Epidemiology, Strasbourg, France, 17Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France

    Background/Purpose: Therapy  with biological agents may be associated with opportunistic infections (OIs). Data on the occurrence of OIs in patients with RA treated with rituximab…
  • Abstract Number: 1280 • 2012 ACR/ARHP Annual Meeting

    Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment Over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors

    Edward Keystone1, Stanley B. Cohen2, Paul Emery3, Joel M. Kremer4, Maxime R. Dougados5, James E. Loveless6, Carol Chung7, Pamela Wong7, Patrica B. Lehane8 and Helen Tyrrell8, 1The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, 2Metroplex Clinical Research Center, Dallas, TX, 3Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 4Center for Rheumatology, Albany Medical College, Albany, NY, 5Hopital Cochin, René Descartes University, Paris, France, 6St Luke's Rheumatology, Boise, ID, 7Genentech, Inc., South San Francisco, CA, 8Roche Products Limited, Welwyn Garden City, United Kingdom

    Background/Purpose: In the REFLEX study conducted in anti-TNF inadequate responder (TNF-IR) patients with RA, a single course of rituximab (RTX) in combination with methotrexate (MTX)…
  • Abstract Number: 1273 • 2012 ACR/ARHP Annual Meeting

    Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment?

    Noortje van Herwaarden1, Aatke van der Maas1, Tim L. Jansen2, Ellen Dutmer3, Andre Hartkamp4, Piet L.C.M. van Riel5, Wietske Kievit5, Bart J.F. van den Bemt6 and Alfons A. den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Rheumatology, Radboud UMC, Nijmegen, Netherlands, 3Rheumatology, Gelderse Vallei Hospital, Ede, Netherlands, 4Reumatology, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, 5Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: The optimal retreatment strategy for rituximab is not clear1. Different strategies are being used in clinical practice, including: on demand retreatment when disease activity…
  • Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting

    A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers

    Susanne Drynda1, David Leesch2, Marietta Gloetzner2 and Joern Kekow2, 1Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, 2Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany

    Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…
  • Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting

    B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases

    Ilias Lazarou1, Axel Finckh2, Lara Fischer3, Camillo Ribi3, Joerg Seebach3 and Pierre A. Guerne2, 1University Hospitals of Geneva, Geneva, Switzerland, 2Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, 3Immunology, University Hospitals of Geneva, Geneva, Switzerland

    Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology